ESR1 and breast cancer: A recent study reported that the ratio of AR to ER in BC dictates the response to AR-targeted therapies, supporting the hypothesis of the clinical efficacy of enzalutamide in selected ER+ tumors with a low AR/ER ratio and AR agonists, such as RAD140, in tumors with a high AR/ER ratio [181].